Table 2.
Correlations between PWV, body composition, metabolic parameters and medications
| Independent variables | Male (r) | Female (r) |
|---|---|---|
| Age | 0.61† | 0.52† |
| Hypertension‡ | 0.19 | 0.59† |
| Type 2 diabetes (yes/no) | 0.46† | 0.18 |
| Visceral fat area (cm2) | -0.18 | 0.25* |
| Fat mass (kg) | -0.26 | 0.06 |
| Fat free mass (kg) | -0.15 | -0.04 |
| apo-B/apoA-1 ratio | -0.29 | 0.10 |
| Fasting insulin (mmol/L) | 0.03 | 0.09 |
| HOMA IR§ | 0.10 | 0.13 |
| Fasting glucose (mmol/L) | 0.35* | 0.24* |
| HbA1c (%) | 0.27 | 0.31* |
| β-blocker (yes/no) | 0.12 | 0.39† |
| Calsium-channel blocker (yes/no) | 0.36* | 0.24* |
| Inhibitors of the RAA-system (yes/no) | 0.29* | 0.14 |
| Statins (yes/no) | 0.39* | 0.22 |
*p < 0.05. †p < 0.001. ‡ Hypertension is defined by the patient receiving antihypertensive medication or having systolic bloodpressure ≥ 140 mmHg or diastoic blood pressure ≥ 90 mmHg. §Homeostasis Model Assessment Insulin Resistance